drugset / Trial / NCT02583269
Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
Phase 1
Completed
24 enrolled
Wake Forest University Health Sciences
National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase I trial studies the side effects and the best dose of muscadine grape skin extract (MGE) in treating patients with malignancy (tumor or cancer) that has spread to other parts of the body or cannot be removed by surgery. MGE is a nutritional supplement containing an extract of the skin of muscadine grape that has shown anti-cancer activity in laboratory studies and may be able to fight or kill malignant cells.
Timeline
- Start
- 2016-03
- Primary completion
- 2017-12-19
- Completion
- 2023-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Muscadine Grape Skin Extract | Unknown | 320 mg | Oral |
| Subject | Muscadine Grape Skin Extract | Unknown | 1600 mg | Oral |